J&J hands off non-opioid painkiller to an upstart in the race for next-gen analgesics

Still facing billions in potential liability for its alleged role in the opioid epidemic, J&J announced a global out-licensing deal for one of its non-opioid painkiller candidates and a suite of backup compounds.

The NJ-based giant signed the deal with the Palo Alto biotech upstart Neumentum. No figures were given.